NASDAQ:CCXI - ChemoCentryx Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ChemoCentryx Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $41.27 +0.53 (+1.30 %) (As of 01/24/2020 04:00 PM ET) Add Compare Today's Range$40.35Now: $41.27▼$43.0850-Day Range$29.63MA: $36.41▼$43.6652-Week Range$6.16Now: $41.27▼$44.21Volume504,103 shsAverage Volume694,170 shsMarket Capitalization$2.40 billionP/E RatioN/ADividend YieldN/ABeta2.28 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CCXI Previous Symbol CUSIP16383L10 CIK1340652 Webhttp://www.chemocentryx.com/ Phone650-210-2900Debt Debt-to-Equity Ratio0.32 Current Ratio3.12 Quick Ratio3.12Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$42.88 million Price / Sales55.87 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book142.31Profitability EPS (Most Recent Fiscal Year)($0.76) Net Income$-37,970,000.00 Net Margins-143.30% Return on Equity-88.76% Return on Assets-23.42%Miscellaneous Employees76 Outstanding Shares58,050,000Market Cap$2.40 billion Next Earnings Date3/9/2020 (Estimated) OptionableOptionable Receive CCXI News and Ratings via Email Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CCXI Rates by TradingView ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions What is ChemoCentryx's stock symbol? ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI." How were ChemoCentryx's earnings last quarter? ChemoCentryx Inc (NASDAQ:CCXI) posted its quarterly earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.06. The biopharmaceutical company earned $10.58 million during the quarter, compared to analyst estimates of $7.83 million. ChemoCentryx had a negative net margin of 143.30% and a negative return on equity of 88.76%. View ChemoCentryx's Earnings History. When is ChemoCentryx's next earnings date? ChemoCentryx is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for ChemoCentryx. What price target have analysts set for CCXI? 7 analysts have issued 12-month price targets for ChemoCentryx's stock. Their forecasts range from $22.00 to $60.00. On average, they expect ChemoCentryx's stock price to reach $44.67 in the next year. This suggests a possible upside of 8.0% from the stock's current price. View Analyst Price Targets for ChemoCentryx. What is the consensus analysts' recommendation for ChemoCentryx? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ChemoCentryx. What are Wall Street analysts saying about ChemoCentryx stock? Here are some recent quotes from research analysts about ChemoCentryx stock: 1. According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (1/3/2020) 2. HC Wainwright analysts commented, "We base our $23 price target on probability adjusted revenue forecasts for avacopan in AAV and C3G. We use the net present value of our revenue forecast through 2028, apply a 30% probability of success (POS) for avacopan in AAV, a 25% POS for avacopan in C3G, a 3x price/sales multiple, and use our estimated fully diluted year end 2019 net cash of $2.54/share to arrive at our price target. Our P/S multiple of 3x is in-line with ChemoCentryx’s peers that range between 2-5x." (5/7/2019) Has ChemoCentryx been receiving favorable news coverage? Headlines about CCXI stock have been trending somewhat negative on Friday, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ChemoCentryx earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for ChemoCentryx. Are investors shorting ChemoCentryx? ChemoCentryx saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 2,030,000 shares, a decline of 29.5% from the December 15th total of 2,880,000 shares. Based on an average trading volume of 1,170,000 shares, the short-interest ratio is currently 1.7 days. Approximately 5.0% of the shares of the company are sold short. View ChemoCentryx's Current Options Chain. Who are some of ChemoCentryx's key competitors? Some companies that are related to ChemoCentryx include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of ChemoCentryx own? Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer LP Unit (ET), Arrowhead Pharmaceuticals (ARWR), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Amicus Therapeutics (FOLD), Opko Health (OPK), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD) and Amarin (AMRN). Who are ChemoCentryx's key executives? ChemoCentryx's management team includes the folowing people: Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 60)Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 56)Dr. Rajinder Singh, Sr. VP of Research (Age 52)Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 66)Dr. Markus J. Cappel, Sr. VP, Chief Bus. Officer & Treasurer (Age 58) Who are ChemoCentryx's major shareholders? ChemoCentryx's stock is owned by many different of institutional and retail investors. Top institutional investors include Zurcher Kantonalbank Zurich Cantonalbank (0.00%). Company insiders that own ChemoCentryx stock include Geoffrey M Parker, James L Tyree, Markus J Cappel, Plc Glaxosmithkline, Pui San Kwan, Rajinder Singh, Susan M Kanaya and Thomas J Schall. View Institutional Ownership Trends for ChemoCentryx. Which institutional investors are buying ChemoCentryx stock? CCXI stock was bought by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for ChemoCentryx. How do I buy shares of ChemoCentryx? Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is ChemoCentryx's stock price today? One share of CCXI stock can currently be purchased for approximately $41.34. How big of a company is ChemoCentryx? ChemoCentryx has a market capitalization of $2.40 billion and generates $42.88 million in revenue each year. The biopharmaceutical company earns $-37,970,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. ChemoCentryx employs 76 workers across the globe.View Additional Information About ChemoCentryx. What is ChemoCentryx's official website? The official website for ChemoCentryx is http://www.chemocentryx.com/. How can I contact ChemoCentryx? ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected] MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 268 (Vote Outperform)Underperform Votes: 253 (Vote Underperform)Total Votes: 521MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/24/2020 by MarketBeat.com StaffFeatured Article: Compound Annual Growth Rate (CAGR)
